De Kraker J, Hoefnagel C A, Caron H, Valdés Olmos R A, Zsiros J, Heij H A, Voûte P A
Emma Kinderziekenhuis/AMC, Amsterdam, The Netherlands.
Eur J Cancer. 1995;31A(4):600-2. doi: 10.1016/0959-8049(95)00063-o.
33 previously untreated advanced stage neuroblastoma patients were treated with [131I]meta-iodobenzylguanidine (MIBG). The number of treatments varied between 2 and 7 per patient (mean 3). Toxicity was seldom severe. Only thrombocytopenia WHO-grade 4 was noticed. Response was documented before surgery for the primary tumour was performed. There was one complete response (CR), 18 partial responses (PR), 11 had stable disease (SD) and 3 had progressive disease (PD). After MIBG therapy and surgery, 12 of 33 patients achieved a CR. This approach is feasible, comparable to multidrug chemotherapy in efficacy and less toxic. Long term results are not known yet.
33例先前未经治疗的晚期神经母细胞瘤患者接受了[131I]间碘苄胍（MIBG）治疗。每位患者的治疗次数在2至7次之间（平均3次）。毒性很少严重。仅观察到4级血小板减少症。在对原发性肿瘤进行手术前记录了反应。有1例完全缓解（CR），18例部分缓解（PR），11例病情稳定（SD），3例病情进展（PD）。MIBG治疗和手术后，33例患者中有12例达到CR。这种方法是可行的，在疗效上与多药化疗相当且毒性较小。长期结果尚不清楚。
